ramucirumab

Known as: Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2, Monoclonal Antibody HGS-ETR2, anti-TRAIL R2 mAb HGS-ETR2 
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1963-2018
05010019632018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Mapatumumab (TRM-1, HGS-ETR1) is a fully human agonistic monoclonal antibody that targets and activates tumor necrosis… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?